

Cover Story
CHICAGO—The consequences of diminishing federal support for cancer research can be measured in the abstracts presented at the 50th annual meeting of the American Society of Clinical Oncology that concluded earlier this week.
By Tessa Vellek
In Brief


Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show
- Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds
- Reforms pending at USPSTF, plus, FDA rejects promising melanoma drug for the second time
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members










